Background Cardiovascular (CV) disease is the leading cause of morbidity and mortality in patients with type 2 diabetes mellitus (T2DM). Furthermore, patients with T2DM and acute coronary syndrome (ACS) have a particularly high risk of CV events. The glucagonlike peptide 1 receptor agonist, lixisenatide, improves glycemia, but its effects on CV events have not been thoroughly evaluated.
The increasing prevalence of type 2 diabetes mellitus (T2DM) represents a significant public health concern due to its cardiovascular (CV) and concomitant long-term health consequences. 1, 2 Epidemiological studies have demonstrated that patients with T2DM have both a 2-to 3-fold increased risk for the development of CV disease, [1] [2] [3] and N60% of deaths are secondary to CV complications. 4 Because patients with T2DM and acute coronary syndrome (ACS) are at particularly high risk for morbidity and mortality despite modern therapies, 5, 6 the identification of cardioprotective therapies is especially important.
The glucagon-like peptide 1 receptor agonists (GLP-1RAs) are glucose-lowering agents that may have beneficial CV effects. 7 The US Food and Drug Administration (FDA) 8 and the European Medicines Agency 9 have established guidelines for phase II/phase III clinical trials to ensure that new therapies for diabetes are not associated with increased CV risk. These recommendations, prompted by adverse CV effects of other glucose-lowering agents, [10] [11] [12] specified enrollment of high-risk participants, minimum treatment exposure of 18 to 24 months, blinded central adjudication of CV events, and sufficient number of events to exclude a 30% increase in risk. The ELIXA trial was designed to test the efficacy and safety of the GLP-1RA, lixisenatide. In this article, we describe the rationale for using lixisenatide, trial design, and randomized patient characteristics.
Rationale
Glucose-lowering therapy and CV risk Evidence-based primary and secondary CV risk reduction strategies, such as the use of statins, 13, 14 angiotensinconverting enzyme inhibitors, and β-blockers, [15] [16] [17] are effective in patients with T2DM. However, the role of glycemic control in CV risk reduction is less clear. A meta-analysis of clinical trials suggested that intensive glycemic control in patients with T2DM reduced the risk of nonfatal myocardial infarction (MI) but did not reduce total or CV-related mortality. 18 Furthermore, safety concerns about glucose-lowering agents in patients with coronary heart disease have been raised, [19] [20] [21] and data demonstrate that sulfonylureas inhibit protective ischemic preconditioning 10, 11 and thiazolidinediones and 1 dipeptidyl peptidase 4 (DPP-4) inhibitor increase heart failure (HF) risk. 12, 22 Glucagon-like peptide 1 receptor agonists. Glucagon-like peptide 1 (GLP-1) is a gastrointestinal hormone that potentiates glucose-dependent insulin release and inhibits glucagon secretion, thereby decreasing hepatic glucose production, lowering basal and postprandial blood glucose, and promoting weight loss by enhancing satiety. The therapeutic utility of native GLP-1 is limited by its rapid degradation by the enzyme DPP-4. Consequently, GLP-1RAs were developed to retain many biological actions of native GLP-1 while extending its half-life by preventing enzymatic degradation. Glucagon-like peptide 1 receptor agonists improve glycemic control with minimal hypoglycemia and enhance weight loss. 23, 24 Lixisenatide is a once-daily GLP-1RA that lowers both fasting and postprandial blood glucose. 25 It has been evaluated in the treatment of T2DM as monotherapy 26 and as add-on therapy with oral agents 27 or basal insulins [28] [29] [30] [31] and both oral agents and basal insulins. 29, 32 Clinical trials show that lixisenatide reduced glycated hemoglobin (HbA1c) by 0.9% in monotherapy, 26 0.8% to 0.9% in combination with an oral agent, 27 and 0.7% when added to basal insulin and oral agent. 29 Lixisenatide also reduced weight 27, 33 and was associated with low risk of hypoglycemic events. 34 Nonetheless, lixisenatide's long-term CV safety and benefit in patients with T2DM and ACS have not been established.
Acute coronary syndrome. Patients with an ACS and T2DM are at a significantly increased risk for mortality, recurrent MI, and HF compared to those without T2DM. 6, 35, 36 Several factors may contribute to this diabetes-associated risk, including concomitant conditions such as renal insufficiency and hypertension, greater cardiac dysfunction, proinflammatory and prothrombotic states, greater burden of atherosclerosis, and detrimental effects of hyperglycemia and insulin resistance. 37, 38 Because of the increasing prevalence of T2DM and the greater risk of adverse outcomes in individuals with T2DM and ACS, it is important to assess the CV effects of glucose-lowering agents.
Methods
Study design and objectives ELIXA (www.clinicaltrials.gov no. NCT01147250) is a randomized, double-blind, placebo-controlled, parallel-group, multicenter phase III event-driven trial designed to assess the effects of lixisenatide added to current T2DM therapy on CV morbidity and mortality in patients with a recent ACS. The primary outcome is the composite of CV death, nonfatal MI, nonfatal stroke, or hospitalization for unstable angina (UA). Secondary trial objectives include the examination of lixisenatide's effects on composite end points including CV death, nonfatal MI, nonfatal stroke, hospitalization for UA, hospitalization for HF, or coronary revascularization. Another trial objective is to assess the safety and tolerability of lixisenatide in patients with T2DM and ACS.
Population recruitment
The inclusion and exclusion criteria are listed in Table I . Patients with T2DM were identified and screened for a spontaneous ACS within 180 days following the hospital admission for the ACS but after discharge. Patients could have T2DM diagnosed by World Health Organization criteria before or after the qualifying ACS. 39 Acute coronary syndrome was defined as an ST-segment elevation MI (STEMI), non-STEMI, or UA. The clinical presentation required admission to an acute care facility and elevation of a cardiac biomarker (troponin or creatine kinase-MB isoenzyme [CK-MB]) above the reference range for MI or intermediate range for UA.
Randomization and study treatment
Eligible patients entered a run-in period of 7 (+3) days (online Appendix A). Patients were trained in selfadministration of daily subcutaneous injections of volume-matched placebo (equivalent to 10 μg/d lixisenatide). At the end of the run-in period, eligible patients were randomized 1:1 to lixisenatide or volume-matched placebo for the double-blinded study treatment. In accordance with protocol (online Appendix B), the dose could be down-or up-titrated to a maximum of 20 μg/d in the absence of symptoms, such as hypoglycemia or gastrointestinal distress. Glycemic control will be managed according to the best judgment of site investigators and informed by clinical practice guidelines. Adjustment of background and investigational drug treatment will be permitted, as is the prescription of other glucose-lowering medications, excluding GLP-1RAs and DPP-4 inhibitors (online Appendix B).
End points and safety assessment
The ELIXA end points are listed in Table II and defined in online Appendix C. In addition to analysis of all reported adverse events, hypoglycemia will be systematically assessed at each visit. Symptomatic hypoglycemia was defined as symptoms consistent with hypoglycemia, blood glucose b60 mg/dL (3.3 mmol/L), and/or prompt recovery after treatment. Severe hypoglycemia was defined as symptomatic hypoglycemia requiring assistance by another person, blood glucose b36 mg/dL (2.0 mmol/L), and/or prompt recovery after treatment. Prespecified safety end points will be monitored, including local injection site or allergic reactions and suspected pancreatitis or pancreatic cancer.
Statistical analysis
Sample size determination. Recruitment of 6,000 patients was projected to occur over 37 months with at least 10 months of follow-up for the last randomized patient. This event-driven study was designed to continue until 844 positively adjudicated events for the primary composite CV end point occurred, assuming a 10% annual event rate for the first year and a 7% annual event rate subsequently. This prespecified number of events was estimated to provide 96% power to demonstrate noninferiority of lixisenatide over placebo with the 1.3 noninferiority boundary, assuming a true risk ratio (RR) of 1.0, and 90% power to demonstrate superiority of lixisenatide over placebo, assuming a RR of 0.80.
Primary end point analyses. The primary efficacy analysis will be performed according to the intent-to-treat principle. All randomized patients will be followed up to the end of study for all nonfatal outcomes. The time to the first occurrence of the primary composite CV end point will be analyzed using a Cox proportional hazards model with treatment (lixisenatide and placebo) and geographical region as fixed-effect factors. Treatment effects across subgroups of gender, age, race, and duration of T2DM will be examined similarly. The HR and 2-sided 95% CI between lixisenatide and placebo will be estimated. Noninferiority of lixisenatide versus placebo will be established if the upper bound of the 2-sided 95% CI of the HR is b1.3, in accordance with the FDA's requirement to confirm CV safety of lixisenatide. Next, the superiority of lixisenatide over placebo will be established if the upper bound of the 2-sided 95% CI of the HR is b1.0. The P value will be calculated using the log-rank test for descriptive purposes.
Study organization and leadership
ELIXA was designed and will be managed by an executive committee comprising clinical experts in both cardiology and diabetes who are based in academic medical centers and sponsor representatives with clinical and methodological expertise in diabetes and clinical trials. The executive committee will assume responsibility for data integrity and interpretation, study content, and the primary manuscript. Additional committees established to ensure trial integrity as well as study drug safety and tolerability include a data monitoring committee consisting of members independent from the executive committee and sponsor to monitor patient safety; a CV event adjudication committee to evaluate and adjudicate, in a blinded fashion, all potential end points; a glycemia committee composed of endocrinologists to provide glycemic control support for site investigators and to ensure patient safety from hypoglycemia; an allergic reaction assessment committee composed of clinical immunologists independent of the sponsor and investigators and blinded to study treatment to assess allergic or allergic-like reactions; and a pancreatic safety assessment committee to review all pancreatic adverse events, including suspected pancreatitis and pancreatic cancer (online Appendix D).
ELIXA was approved by the appropriate institutional or central review boards. All trial participants provided written informed consent. This study was sponsored solely by Sanofi, and the authors were solely responsible for study design. The authors will be solely responsible for completion of the final manuscript, and statistical analyses (performed by the academic statistician and validated by the sponsor's statistician).
Results
Screening and enrollment into ELIXA began June 24, 2010 , and randomization was completed on August 2, 2013. There were 7,718 candidates screened and 6,068 participants randomized to either lixisenatide or placebo (online Appendix A) from 49 countries across 6 regions (online Appendix E) with the support of 782 principal investigators (online Appendix F). One additional candidate was screened and randomized but excluded from analysis due to inadequate consent. Baseline data include data available and validated as of June 29, 2014. Baseline clinical characteristics of the randomized population are shown in Table III . The mean ± SD age was 60.3 ± 9.7 years, 69.3% were male, and 75.2% were white. The index ACS events were STEMI (44.0%), non-STEMI (38.7%), and UA (17.2%). The mean ± SD duration between qualifying ACS and screening was 64.0 ± 43.6 days, and 61.7% of individuals had a percutaneous coronary intervention (PCI) after their ACS. The mean ± SD duration of T2DM was 9.3 ± 8.3 years, HbA1c was 7.7% ± (Table IV) . Relevant CV and diabetic history before the qualifying ACS event is provided in Table V .
Discussion
ELIXA will determine the effects of lixisenatide, a GLP-1RA, compared to placebo on the burden of CV disease in patients with T2DM and ACS. Although native GLP-1 and GLP-1RAs exert favorable CV effects in animal models of MI and ischemia/reperfusion injury, [40] [41] [42] few data exist in humans. In small placebo-controlled studies, GLP-1RA treatment improved myocardial salvage and reduced infarct size. 43, 44 A larger retrospective analysis revealed that the nonrandomized use of GLP-1RA was associated with a 19% lower CV event risk compared with other glucose-lowering agents. 45 In addition, a metaanalysis revealed a significant reduction in CV events among individuals taking GLP-1RAs rather than placebo or other glucose-lowering agents. 46 Therefore, ELIXA has been designed and powered to verify the CV safety of lixisenatide by demonstrating FDA-mandated noninferiority to placebo and to assess superiority in CV outcomes once noninferiority has been established.
To date, prior randomized CV studies of glycemic agents have demonstrated mixed and, sometimes, unexpected results. In the PROactive study, the thiazolidinedione, pioglitazone, reduced the secondary composite end point of nonfatal MI, stroke, and death but was associated with increased HF events. 47 Although a meta-analysis suggested rosiglitazone increased ischemic events, the RECORD trial demonstrated no effect on CV events or mortality, although HF events were increased. 48 Recently, CV trials of the DPP-4 inhibitors, saxagliptin (SAVOR-TIMI 53) 49 and alogliptin (EXAMINE), 50 demonstrated noninferiority compared to placebo for primary CV efficacy end points, but superiority was not demonstrated. Notably, an increase in HF hospitalizations was observed with saxagliptin. 49 A phase III clinical trial of aleglitazar, a combined peroxisome proliferator-activated receptor-α/γ agonist (ALECARDIO), was halted due to safety and efficacy concerns, despite favorable effects on HbA1c and lipids. 51 Finally, a pragmatic design CV outcome trial (TECOS) is currently investigating the CV safety of the DPP-IV inhibitor, sitagliptin, in more than 14,000 patients with T2DM and vascular disease. 52 These studies highlight the importance of CV outcome trials in patients with T2DM.
Several trials are ongoing or planned to investigate the safety and efficacy of GLP-1RAs in patients with high CV risk (online Appendix G). LEADER, a phase IIIB placebocontrolled trial, is evaluating the CV safety of liraglutide in patients with T2DM. 53 In addition, studies of exenatide, dulaglutide, and semaglutide will focus on patients with T2DM and either established or high risk for CV disease. ELIXA will be the first to report long-term CV outcomes of a GLP-1RA in patients with T2DM and recent ACS event.
